Found: 3
Select item for more details and to access through your institution.
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
- Published in:
- Nutrients, 2022, v. 14, n. 21, p. 4673, doi. 10.3390/nu14214673
- By:
- Publication type:
- Article
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
- Published in:
- Nutrients, 2022, v. 14, n. 12, p. 2414, doi. 10.3390/nu14122414
- By:
- Publication type:
- Article
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1240263
- By:
- Publication type:
- Article